Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $980.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective upped by Cantor Fitzgerald from $795.00 to $980.00 in a research note issued to investors on Monday morning,Benzinga reports. Cantor Fitzgerald currently has an overweight rating on the biopharmaceutical company’s stock.

A number of other research analysts have also recently commented on REGN. Wells Fargo & Company boosted their target price on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the stock an “equal weight” rating in a research report on Friday, July 31st. Zacks Research raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, September 28th. TD Cowen raised their price target on shares of Regeneron Pharmaceuticals from $960.00 to $980.00 and gave the company a “buy” rating in a report on Wednesday, October 21st. Guggenheim lifted their price target on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. Finally, Royal Bank Of Canada boosted their price objective on shares of Regeneron Pharmaceuticals from $737.00 to $810.00 and gave the stock a “sector perform” rating in a report on Thursday, October 8th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $898.97.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $930.67 on Monday. The stock’s 50 day moving average price is $800.69 and its 200 day moving average price is $741.11. The firm has a market capitalization of $95.82 billion, a PE ratio of 20.38, a price-to-earnings-growth ratio of 1.45 and a beta of 0.10. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.66 and a current ratio of 3.35. Regeneron Pharmaceuticals has a one year low of $591.52 and a one year high of $991.73.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share for the quarter, topping analysts’ consensus estimates of $16.51 by $3.56. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The firm had revenue of $5.12 billion during the quarter, compared to analysts’ expectations of $4.58 billion. During the same quarter in the prior year, the business earned $11.83 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up 36.3% compared to the same quarter last year. As a group, sell-side analysts expect that Regeneron Pharmaceuticals will post 51.64 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 3rd. Stockholders of record on Friday, November 20th will be paid a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Friday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio is 8.30%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, EVP Joseph Larosa sold 4,466 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $965.49, for a total value of $4,311,878.34. Following the completion of the sale, the executive vice president owned 38,906 shares in the company, valued at approximately $37,563,353.94. The trade was a 10.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Christine Poon sold 7,830 shares of the company’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $969.09, for a total transaction of $7,587,974.70. Following the completion of the sale, the director directly owned 5,219 shares in the company, valued at $5,057,680.71. This represents a 60.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 20,789 shares of company stock valued at $18,766,698. Corporate insiders own 6.97% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Western Wealth Management LLC bought a new position in shares of Regeneron Pharmaceuticals in the first quarter worth $26,000. Armstrong Advisory Group Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 466.7% during the third quarter. Armstrong Advisory Group Inc. now owns 34 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 28 shares during the period. Activest Wealth Management raised its stake in shares of Regeneron Pharmaceuticals by 780.0% during the third quarter. Activest Wealth Management now owns 44 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 39 shares in the last quarter. Alpine Bank Wealth Management bought a new stake in shares of Regeneron Pharmaceuticals during the third quarter valued at about $34,000. Finally, Mowery & Schoenfeld Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals in the second quarter worth about $29,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Bank of America added REGN to its Value 10 list, a favorable signal about the stock’s value appeal. BofA adds REGN to Value 10 list
• Positive Sentiment: Recent analyst coverage points to higher price targets and expectations for appreciation. Separately, Zacks said solid earnings-estimate revisions could help the shares continue gaining. These views follow Regeneron’s recent quarterly results, which beat consensus on earnings and revenue. RBC raises Regeneron price target Zacks on earnings estimate revisions
• Negative Sentiment: Recent disclosures show EVP Joseph Larosa sold 4,466 shares and director Christine Poon sold 7,830 shares on November 2; Poon’s sale cut her direct holding by 60%. Director Kathryn Guarini also sold 400 shares under a pre-arranged trading plan. The larger transactions could raise concerns about insider sentiment, though sales alone do not indicate a change in the company’s business outlook. Larosa sale filing Poon sale filing Guarini sale filing

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.